about
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysisNeutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.Psychological care of caregivers, nurses and physicians: a study of a new approach.Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.Monoclonal gammopathy of undetermined significance: a new proposal of workup.Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.Survey of current practice for monitoring and management of platelet refractoriness in ItalyCorrelation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma
P50
Q33404749-324746D3-BE35-45B3-9C55-0F709C80CF3EQ35009935-FAB835C5-0160-4E11-A94D-2A20BBEBA38CQ36416269-40E8E411-8C90-4AA1-9D1C-9D3B22C34078Q41968577-521D62D0-8603-4833-8F9D-0E1B2672DDE5Q42476592-A464DB69-FD63-4EF1-A400-8A2B95837EB3Q44580273-6EE97FCA-B9A1-44BB-8238-8833524B055EQ46057559-A6E63A37-0AE0-431F-BDFF-EA281F57069DQ84249920-EEABFDDD-0939-4509-8E68-41BA9FA5599BQ86870307-40CC1A86-1F12-4F11-8A78-4589B5539DED
P50
description
researcher ORCID ID = 0000-0001-8583-4976
@en
wetenschapper
@nl
name
Alessandra Pompa
@ast
Alessandra Pompa
@en
Alessandra Pompa
@es
Alessandra Pompa
@nl
type
label
Alessandra Pompa
@ast
Alessandra Pompa
@en
Alessandra Pompa
@es
Alessandra Pompa
@nl
prefLabel
Alessandra Pompa
@ast
Alessandra Pompa
@en
Alessandra Pompa
@es
Alessandra Pompa
@nl
P106
P1153
55802480200
P31
P496
0000-0001-8583-4976